SciFluor reports Phase I/II data for DME candidate

SciFluor Life Sciences Inc. (Cambridge, Mass.) reported top-line data from a Phase I/II trial in 40 patients with diabetic macular edema (DME) showing that SF0166 Topical Ophthalmic Solution met the primary safety endpoint with no treatment-related serious adverse events reported. Ocular adverse events were reported in the treated eyes of 6 patients and all events were mild in severity.

Additionally, the company said 53% of patients showed a reduction in retinal thickness. Furthermore, there were no significant reductions in visual acuity in study eyes during treatment or follow-up and no patient required rescue treatment with an anti-VEGF injection during treatment...